Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.50 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996181 | 1.00 | TMEM97 (0.51) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL580802 | 0.88 | SMN1; SMN2 (0.51) | TMEM97SIGMAR1ACE2 | |
| SCHEMBL2988175 | 0.86 | AADAT (0.53) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL5160860 | 0.83 | TMEM97 (0.55) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL13374850 | 0.82 | AADAT (0.45) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL29277932 | 0.82 | PREP (0.52) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL582341 | 0.81 | SIGMAR1 (0.45) | TMEM97SIGMAR1 | |
| SCHEMBL2991989 | 0.80 | TMEM97 (0.51) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL2991986 | 0.80 | TMEM97 (0.51) | TMEM97SIGMAR1AADATACE2PREP | |
| SCHEMBL15017542 | 0.80 | SMN1; SMN2 (0.57) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| EP-1907378-A1 | PREPARATION OF TERAZOLE DERIVATIVES | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200687-A1 | Preparation of Terazole Derivatives | TERB1, TALDO1, TERT | TMEM97 2959/4885SIGMAR1 1679/4885AADAT 3098/4885 |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | TERB1, TALDO1, TERT | TMEM97 2959/4885SIGMAR1 1679/4885AADAT 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.